Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Keke granule for refractory chronic cough (Phase 2)
ChiCTR2500114325Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory chronic cough (RCC) comparing Trial group (Fufang Keke granule) with Placebo group (2 arms). Primary endpoint: Proportion of patients with cough VAS improvement ≥30 points from baseline at Day 7. Started Dec 2025; status: recruiting.
02
Drugs
Fufang Keke granule
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on ChiCTR2500114325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114325.